Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17623
Country/Region: Rwanda
Year: 2016
Main Partner: Ministry of Health - Rwanda
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $17,604,259 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,407,170
Care: TB/HIV (HVTB) $691,667
Care: Pediatric Care and Support (PDCS) $239,817
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $2,017,295
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,607,785
Treatment: Adult Treatment (HTXS) $10,281,560
Treatment: Pediatric Treatment (PDTX) $1,358,965
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 1,332
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 1,679
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 4,108
GEND_GBV Number of people receiving post-GBV care 2017 5,789
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 37,927
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 34,548
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 445,500
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 337,049
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 852,880
HTS_TST Service Delivery Point (Community): Mobile testing 2017 49,446
HTS_TST Service Delivery Point (Facility): Index testing 2017 5,369
HTS_TST Service Delivery Point (Facility): Inpatient 2017 13,978
HTS_TST Service Delivery Point (Facility): Other PITC 2017 103,836
HTS_TST Service Delivery Point (Facility): Outpatient 2017 214,438
HTS_TST Service Delivery Point (Facility): PMTCT 2017 130,284
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,584
HTS_TST Service Delivery Point (Facility): VCT 2017 280,668
HTS_TST Service Delivery Point (Facility): VMMC 2017 37,311
HTS_TST Sum of Aggregated Age/Sex <15 2017 72,475
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 782,549
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 855,024
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 164
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 139
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 6,065
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3,561
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,464
PMTCT_ART New on ART 2017 1,137
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 130,361
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,429
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 194
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 43
PMTCT_EID Sum of Infant Age disaggregates 2017 3,623
PMTCT_STAT By: Known positives at entry 2017 2,712
PMTCT_STAT By: Number of new positives identified 2017 1,068
PMTCT_STAT Number of new ANC and L&D clients 2017 132,986
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 130,361
PMTCT_STAT Sum of Positives Status disaggregates 2017 3,780
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 296
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 17
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 554
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 873
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 873
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 8,871
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 6,393
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,485
TB_SCREENDX Screen Result: Screened Positive for TB 2017 8,881
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 60,621
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 32,979
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 2,525
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 2,555
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 98,677
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 43
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 852
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 76
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,594
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 2,567
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 2,567
TX_CURR Aggregated Age/Sex: <15 Female 2017 2,573
TX_CURR Aggregated Age/Sex: <15 Male 2017 2,581
TX_CURR Aggregated Age/Sex: 15+ Female 2017 61,927
TX_CURR Aggregated Age/Sex: 15+ Male 2017 33,737
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 100,794
TX_CURR Sum of Aggregated Age/Sex <15 2017 5,154
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 95,664
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 100,818
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 432
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 404
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 8,995
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 4,899
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 14,752
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 14,730
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 92,709
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 81,642
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,187
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,218
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 50,013
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 27,222
TX_PVLS Numerator: Indication: Routine 2017 67,760
TX_PVLS Numerator: Indication: Targeted 2017 13,531
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,472
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,517
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 56,805
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 30,916
TX_PVLS_den Denominator: Indication: Routine 2017 76,931
TX_PVLS_den Denominator: Indication: Targeted 2017 15,765
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 297
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 263
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,209
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,498
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 10,293
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 10,873
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 322
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 295
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,540
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,717
VMMC_CIRC By Age: 15-19 2017 16,792
VMMC_CIRC By Age: 20-24 2017 15,822
VMMC_CIRC By Age: 25-29 2017 15,345
VMMC_CIRC By circumcision technique: Device-based VMMC 2017 23,884
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 23,881
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 47,967
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 47,959
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 32,614
Cross Cutting Budget Categories and Known Amounts Total: $8,720,600
Human Resources for Health $8,540,000
Food and Nutrition: Policy, Tools, and Service Delivery $40,600
Key Populations: MSM and TG $25,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Key Populations: Sex Workers $35,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Gender: Gender Based Violence (GBV) $80,000
Post GBV Care
Implementation
Capacity building